Linked e-resources
Details
Table of Contents
Preface; Contents; List of Contributors; About the Editors; Part I: Targeted Drug Delivery: Basic Concepts and Advances; Chapter 1: Targeted Drug Delivery Systems: Strategies and Challenges; 1.1 Introduction; 1.2 Targeted Drug Delivery: General Concepts; 1.2.1 Passive (Physiology-Based) Targeting; 1.2.2 Active Targeting; 1.2.2.1 Targeting Mediated by External Stimuli; 1.2.2.2 Antibody-Directed Enzyme Prodrug Therapy (ADEPT); 1.2.2.3 Targeting in Gene Therapy; 1.3 Targeted Drug Delivery: Disease-Based Strategies; 1.3.1 Cancer Specific Strategies; 1.3.2 Targeted Drug Delivery Towards Infections
1.3.2.1 Tuberculosis (TB)1.3.2.2 Malaria; 1.3.2.3 Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS); 1.4 Targeted Drug Delivery: Specific Location-Based Strategies; 1.4.1 Blood-Brain Barrier (BBB) Targeted Delivery; 1.4.2 Targeting Drug Delivery to the Skin with Highlight on the Follicular Pathway; 1.4.3 Pulmonary Targeted Drug Delivery; 1.4.4 Retina; 1.4.5 Colon Targeted Drug Delivery; 1.4.6 Intracellular Targeting; 1.5 Summary; 1.6 Conclusion; References; Part II: Disease-Based Targeting; Chapter 2: Recent Advances in Tumor Targeting Approaches; 2.1 Introduction
2.2 Normal Vs Tumor Vasculature2.3 Barriers to Tumor Targeting; 2.4 Conventional Strategies for Tumor Targeting; 2.4.1 Passive Targeting; 2.4.1.1 Enhanced Permeation and Retention (EPR) Effect; 2.4.1.2 Surface Engineering of Colloidal Carriers for Stealth Characteristics; 2.4.2 Active Targeting; 2.4.2.1 Albumin Based Targeting; 2.4.2.2 Vitamin Based Targeting; 2.4.2.3 Transferrin Based Targeting; 2.4.2.4 Lectin Based Targeting; 2.4.2.5 Peptide Based Targeting; 2.4.3 Physical Targeting; 2.5 Recent Advances in Tumor Targeting Approaches; 2.5.1 Molecular Targeted Therapies
2.5.1.1 Agents Acting on Protein Folding and Proteotoxic Stresses2.5.1.2 Proteasome Inhibitors; 2.5.1.3 Targeting Chromatin Modifications; 2.5.2 Tumor Angiogenesis; 2.5.3 Cancer Immunotherapy; 2.5.3.1 Radioimmunotherapy (RAIT); 2.5.3.2 Immunotoxins; 2.5.3.3 Immunocytokines; 2.5.3.4 Antibody Directed Enzyme Prodrug Therapy (ADEPT); 2.5.3.5 Immunoliposomes; 2.5.3.6 Immunopolymers; 2.5.4 Targeting Multidrug Resistant Tumors; 2.6 Conclusion and Future Prospects; References; Chapter 3: Infectious Diseases: Need for Targeted Drug Delivery; 3.1 Infectious Diseases in the Modern World
3.1.1 Extracellular and Intracellular Infectious Diseases3.2 Reticuloendothelial System and Intracellular Infections; 3.2.1 Opsonisation; 3.2.2 Phagocytosis; 3.2.3 Macrophages; 3.2.3.1 Activated Macrophages (M1); 3.2.3.2 Alternative Activated Macrophages (M2); 3.2.4 Survival Mechanisms Adapted by Pathogens; 3.2.4.1 Inhibition of Phagolysosome Formation; 3.2.4.2 Fusion of Endosome with Cell Organelles Other than Lysosome; 3.2.4.3 Disruption of the Phagolysosome; 3.2.4.4 Survival in the Late Phagolysosomes; 3.2.4.5 Internalisation by Non-phagocytic Pathways or by Parasitophorous Vacuole
1.3.2.1 Tuberculosis (TB)1.3.2.2 Malaria; 1.3.2.3 Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS); 1.4 Targeted Drug Delivery: Specific Location-Based Strategies; 1.4.1 Blood-Brain Barrier (BBB) Targeted Delivery; 1.4.2 Targeting Drug Delivery to the Skin with Highlight on the Follicular Pathway; 1.4.3 Pulmonary Targeted Drug Delivery; 1.4.4 Retina; 1.4.5 Colon Targeted Drug Delivery; 1.4.6 Intracellular Targeting; 1.5 Summary; 1.6 Conclusion; References; Part II: Disease-Based Targeting; Chapter 2: Recent Advances in Tumor Targeting Approaches; 2.1 Introduction
2.2 Normal Vs Tumor Vasculature2.3 Barriers to Tumor Targeting; 2.4 Conventional Strategies for Tumor Targeting; 2.4.1 Passive Targeting; 2.4.1.1 Enhanced Permeation and Retention (EPR) Effect; 2.4.1.2 Surface Engineering of Colloidal Carriers for Stealth Characteristics; 2.4.2 Active Targeting; 2.4.2.1 Albumin Based Targeting; 2.4.2.2 Vitamin Based Targeting; 2.4.2.3 Transferrin Based Targeting; 2.4.2.4 Lectin Based Targeting; 2.4.2.5 Peptide Based Targeting; 2.4.3 Physical Targeting; 2.5 Recent Advances in Tumor Targeting Approaches; 2.5.1 Molecular Targeted Therapies
2.5.1.1 Agents Acting on Protein Folding and Proteotoxic Stresses2.5.1.2 Proteasome Inhibitors; 2.5.1.3 Targeting Chromatin Modifications; 2.5.2 Tumor Angiogenesis; 2.5.3 Cancer Immunotherapy; 2.5.3.1 Radioimmunotherapy (RAIT); 2.5.3.2 Immunotoxins; 2.5.3.3 Immunocytokines; 2.5.3.4 Antibody Directed Enzyme Prodrug Therapy (ADEPT); 2.5.3.5 Immunoliposomes; 2.5.3.6 Immunopolymers; 2.5.4 Targeting Multidrug Resistant Tumors; 2.6 Conclusion and Future Prospects; References; Chapter 3: Infectious Diseases: Need for Targeted Drug Delivery; 3.1 Infectious Diseases in the Modern World
3.1.1 Extracellular and Intracellular Infectious Diseases3.2 Reticuloendothelial System and Intracellular Infections; 3.2.1 Opsonisation; 3.2.2 Phagocytosis; 3.2.3 Macrophages; 3.2.3.1 Activated Macrophages (M1); 3.2.3.2 Alternative Activated Macrophages (M2); 3.2.4 Survival Mechanisms Adapted by Pathogens; 3.2.4.1 Inhibition of Phagolysosome Formation; 3.2.4.2 Fusion of Endosome with Cell Organelles Other than Lysosome; 3.2.4.3 Disruption of the Phagolysosome; 3.2.4.4 Survival in the Late Phagolysosomes; 3.2.4.5 Internalisation by Non-phagocytic Pathways or by Parasitophorous Vacuole